This is one of the most pressing and most common questions being asked by patients, especially by patients who have lost significant vision to glaucoma. The loss of vision in glaucoma is associated with the degeneration of retinal ganglion cells (called "RGCs"), and the premise—and promise—of replacing RGCs with stem cells to restore vision is compelling.
Are we making progress towards stem cell treatments?
We've made a lot of progress in the laboratory towards cell therapy for glaucoma. Our lab and others' labs have largely figured out how to turn human stem cells into human RGCs in the lab dish, and we can characterize their function and anatomy with ultrafine molecular detail. Furthermore, human RGC transplants into preclinical model animals with glaucoma or related eye diseases similar to human disease are making more and more progress, showing more promise—although there is still more science to solve—how do we get enough cells transplanted into the retina to improve vision meaningfully? How do we maximize the donor cells' integration into retinal circuitry? How much immunosuppression is needed in the short or longer term?
0 Comments